MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • 2018 International Congress

    Effectiveness of a Multi-disciplinary Parkinson’s Disease (PD) Clinic: A 2-year Prospective Observational Study

    G. Chan, N. Cheung, S. Or, I. Chan, A. Leung, C. Li, D. Chau, C.W. Woo, B. Chee, W.C. Fong (Hong Kong)

    Objective: To evaluate if a multi-disciplinary PD clinic can result in better outcome in PD patients in 2 years. Background: PD is a neurodegenerative disease…
  • 2018 International Congress

    Impact of Subthalamic Nucleus Stimulation on Striatal Dopamine Transporter in Parkinsonian Rat Models

    W. Xian, Q. Guo, L. Jiang, Z. Pei, L. Chen (Guangzhou, China)

    Objective: To investigate the impact of subthalamic nucleus deep brain stimulation (STN-DBS) on striatal dopamine transporter (DAT) of Parkinsonian rat models. Background: STN-DBS has become…
  • 2018 International Congress

    Teed and primary cell longevity: Results from product surveillance registry

    P. Konrad, G. Plotkin, S. Palfi, E. Cuny, J-P. Azulay, T. Witt, T. Theys, Y. Temel, G. Johnson, K. Bhatia, T. Weaver, M. Schiess, J. Krauss, S. Falowski (Nashville, TN, USA)

    Objective: To evaluate the influence of electrical stimulation settings and impedance on primary cell IPG longevity in a global registry. Background: Deep Brain Stimulation (DBS)…
  • 2018 International Congress

    Prevalence of REM Sleep Behavior Disorder in Sun City, Arizona

    D. Shprecher, A. Intorcia, M. Glass, J. Curry, J. Walker, B. Cutler, M. Callan, G. Serrano, N. Zhang, L. Sue, K. Davis, T. Beach (Sun City, AZ, USA)

    Objective: Determine prevalence of REM Sleep Behavior Disorder (RBD) in Sun City, Arizona Background: RBD is the strongest known clinical risk factor for neurodegenerative disorders…
  • 2018 International Congress

    Evolution of Motor and Non-Motor Manifestations in Prodromal Parkinsonism

    SM. Fereshtehnejad, C. Yao, A. Pelletier, J. Montplaisir, JF. Gagnon, R. Postuma (Montreal, QC, Canada)

    Objective: To trace the evolution of early motor and non-motor manifestations of synculeinopathy from the stage of idiopathic REM sleep behavior disorder (iRBD) until defined…
  • 2018 International Congress

    Adolescent onset RBD converting to PD after 48 years

    Z. Xu, J. Oliver, K. Anderson (Singapore, Singapore)

    Objective: To present a patient with adolescent onset dream enactment behaviour who developed PD 48 years later. Background: RBD typically occurs after age 50, and…
  • 2018 International Congress

    The impact of APOε4 polymorphisms and mutations in the GBA gene on the clinical features of Dementia with Lewy Bodies among Ashkenazi Jews

    T. Shiner, A. Mirelman, Y. Rozenblum, G. Kave', M. Gana Weisz, A. Bar-Shira, A. Thaler, T. Gurevich, A. Orr-Urtreger, N. Gilad, N. Bregman (Tel Aviv, Israel)

    Objective: We aimed to explore the frequency and clinical impact of APOε4 polymorphisms in a cohort of Ashkenazi Jewish (AJ) patients with Dementia with Lewy…
  • 2018 International Congress

    Vascular parkinsonism: Clinical features and comparison with Parkinson’s disease

    C. Simonet, A. Garrido, F. Valldeoriola, MJ. Martí, Y. Compta (Barcelona, Spain)

    Objective: To define the clinical features of vascular parkinsonism (VP) and compare it to idiopathic Parkinson’s disease (iPD). Background: The main differential diagnosis of VP…
  • 2018 International Congress

    Role of uric acid as a prognostic biomarker in Idiopathic Parkinson’s disease and Parkinson Plus Syndrome

    T. Modi, M. Goyal, J. Kaur, B. Medhi (Chandigarh, India)

    Objective: To estimate the levels of serum uric acid in Idiopathic Parkinson’s disease (IPD) and various Parkinson plus syndromes (PPS). To correlate the uric acid…
  • 2018 International Congress

    Using saccades as an early test of levodopa treatment in Parkinson’s Disease

    Z.J. Lu, S. Dillon, P. Zetegren, M. Brzezick, C. Kennard, J. FitzGerald, C. (Oxford, United Kingdom)

    Objective: It is important to know what potential confounding effects the medications used to treat Parkinson’s disease (PD) have on eye movement, in order to…
  • « Previous Page
  • 1
  • …
  • 257
  • 258
  • 259
  • 260
  • 261
  • …
  • 425
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley